|
|
|
|
|
Diflucan: profile and news
APS: Brain May Be Important Factor In Heart Disease 06 Mar 2006 Name That Episode! 06 Mar 2006 Antidepressants Double Children's Suicidal Thinking, Study Says 06 Mar 2006 Antidepressants Linked to Modest Risk of Non-Fatal Thoughts in ... 06 Mar 2006 Aurobindo gets Health Canada approval for Citalopram 06 Mar 2006 Aurobindo Pharma gets Canada nod for drug Mar 5, 2006 Beyond guesswork Mar 5, 2006 SSRIs face next-generation replacement Mar 4, 2006 Bentley announces score of Spanish generics approvals Feb 28, 2006 SSRIs: Wonder drugs From Hell Mar 3, 2006 Antidepressants: Are they safe during pregnancy? Feb 22, 2006 Since you asked ... Feb 5, 2006 Monoaminergic Treatment of Schizophrenia Feb 27, 2006 Bentley Pharmaceuticals Provides Update on Product Approvals ... Feb 27, 2006 Jagged little pills Mar 2, 2006 STAR*D Preliminary Findings Provide Clearer Picture of Major ... Feb 27, 2006 Newest First Oldest First Feb 5, 2006 Pregnant women with history of depression weigh drug use Feb 22, 2006 Cutting Certain Pills in Half Can Help Reduce Costs Feb 19, 2006 SSRIs harm baby's breath? Feb 24, 2006 Depression in Pregnancy Poses Treatment Challenge Feb 6, 2006 Antidepressant poses risk to baby Feb 8, 2006 Mom's Antidepressant Use Raises Newborn's Risk for Lung Condition Feb 8, 2006 Antidepressants May Harm Infants' Lungs, Report Says Feb 8, 2006 Maternal Antidepressant Use Can Trigger Withdrawal in Newborns Feb 6, 2006 Antidepressant use in late pregnancy may hurt infants Feb 10, 2006 SSRIs` risk to infants Feb 6, 2006 Antidepressants in Pregnancy Linked to Newborn Hangover Feb 7, 2006 Maternal Antidepressant Use Can Trigger Withdrawal in Newborns Feb 6, 2006 Effects of SSRIs on foetus Feb 7, 2006 Confusing Times for Depressed Pregnant Women--and Their Doctors Feb 8, 2006 Depression - Symptoms, Causes and Treatment options Feb 15, 2006 Good News For Those With The Blues Feb 16, 2006 Splitting pills and splitting bills Feb 5, 2006 Baby blues: Big dilemma? Feb 17, 2006 Depression: initial results help determine successful treatments Feb 3, 2006 Shock Therapy, Version 2.0 Feb 1, 2006 Pregnancy May Not Protect Against Depression Jan 31, 2006 Jossip Wants You: Sell your soul as an intern Feb 1, 2006 Other information Indication For the treatment of fungal infections. Pharmacology Fluconazole, a synthetic antifungal agent of the imidazole class, is used to treat vaginal candidiasis. Mechanism Of Action Fluconazole interacts with 14-α demethylase, a cytochrome P-450 enzyme necessary to convert lanosterol to ergosterol. As ergosterol is an essential component of the fungal cell membrane, inhibition of its synthesis results in increased cellular permeability causing leakage of cellular contents. Fluconazole may also inhibit endogenous respiration, interact with membrane phospholipids, inhibit the transformation of yeasts to mycelial forms, inhibit purine uptake, and impair triglyceride and/or phospholipid biosynthesis. Drug Category Antifungals; Antifungals; ATC:D01AC15; ATC:J02AC01 Brand Names/Synonyms Biocanol; Biozolene; Diflucan; Diflucan in Sodium Chloride 0.9%; Elazor; FLUCONAZOLE , 99%; Flucazol; Fluconazole; Fluconazole in Sodium Chloride 0.9%; Flucostat; Flukezol; Flunizol; Flusol; Pritenzol; Triflucan Dosage Forms CAPSULE; LIQUID; POWDER FOR SOLUTION; SOLUTION; TABLET Absorption 90% Interactions Interactions for Fluconazole: Clinically or potentially significant drug interactions between DIFLUCAN and the following agents/classes have been observed. These are described in greater detail below: DIFLUCAN and the following agents/classes have been observed. These are described in greater detail below: Oral hypoglycemics Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association with combined DIFLUCAN and glyburide use. DIFLUCAN reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these agents. When DIFLUCAN is used concomitantly with these or other sulfonylurea oral hypoglycemic agents, blood glucose concentrations should be carefully monitored and the dose of the sulfonylurea should be adjusted as necessary. Coumarin-type anticoagulants: Prothrombin time may be increased in patients receiving concomitant DIFLUCAN and coumarin-type anticoagulants. In post-marketing experience, as with other azole antifungals, bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported in association with increases in prothrombin time in patients receiving fluconazole concurrently with warfarin. Careful monitoring of prothrombin time in patients receiving DIFLUCAN and coumarin-type anticoagulants is recommended. (See CLINICAL PHARMACOLOGY: Drug Interaction Studies.) Phenytoin: DIFLUCAN increases the plasma concentrations of phenytoin. Careful monitoring of phenytoin concentrations in patients receiving DIFLUCAN and phenytoin is recommended. (See CLINICAL PHARMACOLOGY: Drug Interaction Studies.) Cyclosporine: DIFLUCAN may significantly increase cyclosporine levels in renal transplant patients with or without renal impairment. Careful monitoring of cyclosporine concentrations and serum creatinine is recommended in patients receiving DIFLUCAN and cyclosporine. (See CLINICAL PHARMACOLOGY: Drug Interaction Studies.) Rifampin: Rifampin enhances the metabolism of concurrently administered DIFLUCAN. Depending on clinical circumstances, consideration should be given to increasing the dose of DIFLUCAN when it is administered with rifampin. Theophylline: DIFLUCAN increases the serum concentrations of theophylline. Careful monitoring of serum theophylline concentrations in patients receiving DIFLUCAN and theophylline is recommended. Terfenadine: Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving azole antifungals in conjunction with terfenadine, interaction studies have been performed. One study at a 200-mg daily dose of fluconazole failed to demonstrate a prolongation in QTc interval. Another study at a 400-mg and 800-mg daily dose of fluconazole demonstrated that DIFLUCAN taken in doses of 400 mg per day or greater significantly increases plasma levels of terfenadine when taken concomitantly. The combined use of fluconazole at doses of 400 mg or greater with terfenadine is contraindicated. The coadministration of fluconazole at doses lower than 400 mg/day with terfenadine should be carefully monitored. Cisapride: There have been reports of cardiac events, including torsade de pointes in patients to whom fluconazole and cisapride were coadministered. A controlled study found that concomitant fluconazole 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval.The combined use of fluconazole with cisapride is contraindicated. Astemizole: The use of fluconazole in patients concurrently taking astemizole or other drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these drugs. In the absence of definitive information, caution should be used when coadministering fluconazole. Patients should be carefully monitored. Rifabutin: There have been reports of uveitis in patients to whom fluconazole and rifabutin were coadministered. Patients receiving rifabutin and fluconazole concomitantly should be carefully monitored. Tacrolimus: There have been reports of nephrotoxicity in patients to whom fluconazole and tacrolimus were coadministered. Patients receiving tacrolimus and fluconazole concomitantly should be carefully monitored. Short-acting Benzodiazepines: Following oral administration of midazolam, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects. This effect on midazolam appears to be more pronounced following oral administration of fluconazole than with fluconazole administered intravenously. If short-acting benzodiazepines, which are metabolized by the cytochrome P450 system, are concomitantly administered with fluconazole, consideration should be given to decreasing the benzodiazepine dosage, and the patients should be appropriately monitored. Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; however, in some patients there were decreases up to 47% and 33% of ethinyl estradiol and levonorgestrel levels. The data presently available indicate that the decreases in some individual ethinyl estradiol and levonorgestrel AUC values with fluconazole treatment are likely the result of random variation. While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. The clinical significance of these effects is presently unknown. Physicians should be aware that interaction studies with medications other than those listed in the CLINICAL PHARMACOLOGY section have not been conducted, but such interactions may occur. Chemical IUPAC Name 2-(2,4-difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol Chemical Formula C13H12F2N6O Half Life 30 hours (range 20-50 hours) Drug Type Approved Drug # Accession No APRD00327 CAS Registry Number 86386-73-4 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |